Ensysce Biosciences, Inc. (ENSC) · Nov 4, 2026 · Exec change
CEO-to-COO transition — Kirkpatrick remains COO after the December 14 annual meeting
Ensysce’s executive-change filing formalizes James Morrison’s move to CEO while Lynn Kirkpatrick remains as COO after the December annual meeting.
Ensysce is a clinical-stage biotech now balancing its long-running PF614-MPAR overdose-protection program with CY200, the CRPS therapy added through its 2026 Cy Biopharma acquisition. The company has recently described CY200 as its lead pipeline asset while continuing late-stage work on PF614-MPAR.
The CEO handoff is mostly confirmation, not a new strategic shift. The company had already disclosed that President James Morrison would become CEO after stockholder approval; this filing adds that longtime CEO Lynn Kirkpatrick will move into the COO role rather than leave, preserving day-to-day scientific and operating continuity.
The transition avoids an immediate severance obligation. Kirkpatrick has agreed that accepting the COO position will not trigger severance under her employment agreement, limiting the financial complication of the succession.
The board change adds a small governance uncertainty but no stated operating disruption. Director Will Chang intends to resign after the annual meeting, but he has not submitted a written resignation or specified a date.
Bottom line: This formalizes a previously telegraphed leadership transition while retaining Kirkpatrick inside the operating team. It matters for governance and accountability, but it does not materially rewrite Ensysce’s clinical-development story.
Annual meeting, December 14, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!